It's not possible to predict, and the Regeneron study was limited to patients with poor antibody responses anyhow. Antibodies are also expensive and so far have to be given intravenously. Apabetalone could have a big advantage there

But I don't think we need be concerned about other drugs at present. So far, there are only antibodies and dexamethasone, which have completely different modes of action from apabetalone. If the covid trial is positive, I think the likelihood is that it will be prescribed in addition to other therapies, not instead of.